Indivior
Develops monthly injectable and sublingual medicines for opioid use disorder.
$34.87
After-hours close0.00 (0.00%)
At close$34.87(−1.22%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | $1.06 | — | — |
| Aug 2026 | $0.87 | $1.15 | +32.3% |
| Apr 2026 | $0.64 | $0.96 | +50.0% |
| Feb 2026 | $0.65 | $0.82 | +26.2% |
| Oct 2025 | $0.38 | $0.72 | +89.5% |
The latest year is open to everyone — the 15 quarters behind it read with an account. Sign in | |||
| Jul 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Jul 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Jul 2023 | |||
| Apr 2023 | |||
| Dec 2022 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Oct 29, 2026 | $1.06 | — | — | $329.4M | — | — |
| Aug 3, 2026 | $0.87 | $1.15 | +32.3% | $306.2M | $343.0M | +12.0% |
| Apr 30, 2026 | $0.64 | $0.96 | +50.0% | $272.8M | $317.0M | +16.2% |
| Feb 26, 2026 | $0.65 | $0.82 | +26.2% | $305.6M | $358.0M | +17.1% |
| Oct 30, 2025 | $0.38 | $0.72 | +89.5% | $306.2M | $314.0M | +2.5% |
The latest year is open to everyone — the 15 quarters behind it read with an account. Sign in | ||||||
| Jul 31, 2025 | ||||||
| Apr 24, 2025 | ||||||
| Feb 20, 2025 | ||||||
| Oct 24, 2024 | ||||||
| Jul 25, 2024 | ||||||
| Apr 25, 2024 | ||||||
| Feb 22, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Jul 27, 2023 | ||||||
| Apr 27, 2023 | ||||||
| Dec 30, 2022 | ||||||
| Sep 29, 2022 | ||||||
| Jun 29, 2022 | ||||||
| Mar 30, 2022 | ||||||
| Dec 30, 2021 | ||||||